Press release
Rising Healthcare Expenditure Driving Market Growth: A Significant Driver Propelling The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2025
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
What Is the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Projected Growth Rate?
In recent times, the market size for chronic inflammatory demyelinating polyneuropathy (CIDP) has seen substantial growth. It's projected to expand from $2.10 billion in 2024 to $2.38 billion in 2025, experiencing a compound annual growth rate (CAGR) of 8.4%. This growth during the historic period can be linked to factors such as the rise in the elderly population, enhanced therapeutic options, heightened awareness leading to premature diagnosis, advancements in the research of immunology and autoimmune diseases, and the increasing incidence of autoimmune diseases.
The market size for chronic inflammatory demyelinating polyneuropathy (CIDP) is projected to experience solid expansion in the coming years, reaching $3.11 billion by 2029 with a compound annual growth rate (CAGR) of 8.1%. The surge in the anticipated period can be ascribed to factors such as the world's aging population, increasing emphasis on rare and autoimmune diseases, enhanced healthcare accessibility, initiatives for patient advocacy and awareness, and betterment in healthcare infrastructures. Prime trends for the predicted period encompass a rising prevalence of chronic inflammatory demyelinating polyneuropathy, progress in treatment alternatives, escalating research and development undertakings, introduction of biosimilar therapies, and the evolution of personalized medicine tactics.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
What Are the Major Segments in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented -
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
What Are The Driving Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Evolution?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is predicted to expand in the future due to the escalating costs of healthcare. This increase in healthcare expenditure is a result of heightened investments in medical facilities, a growing need for premium treatment methods, broader insurance provision, and governmental initiatives to improve healthcare availability. Greater spending in healthcare allows for more advanced treatment options, timely detection, and improved handling of CIDP, leading to enhanced patient results and life quality. For example, as reported by the Office for National Statistics, a government department based in the UK, there was a 5.6% nominal hike in the total healthcare expenses from 2022 to 2023, noted in May 2024. This increase is notably higher compared to the 0.9% growth seen in 2022. Consequently, the escalating healthcare expenditure is fueling the expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
Which Firms Dominate The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segments?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
What Trends Are Driving Growth in The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The critical players in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are channeling their efforts towards progressions such as intravenous immunoglobulin (IVIG) therapy to leverage treatment effectiveness and boost patient outcomes, offering more intricate and potent immune regulation for CIDP management. IVIG therapy comprises the injection of concentrated antibodies sourced from healthy contributors to regulate the immune system and diminish inflammation in autoimmune disorders. For instance, Takeda Pharmaceutical Company Limited, a biopharmaceutical firm based in Japan, disclosed FDA endorsement for GAMMAGARD LIQUID as an IVIG therapy for adult patients with CIDP in January 2024. This approval permits its application as an induction therapy, initiating with a primary dose and followed up by sustaining doses to facilitate continuous disease control and enhance neuromuscular activity.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-global-market-report
Which Is The Largest Region In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
2. What is the CAGR expected in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
3. What Are the Key Innovations Transforming the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry?
4. Which Region Is Leading the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.
Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Healthcare Expenditure Driving Market Growth: A Significant Driver Propelling The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2025 here
News-ID: 4069596 • Views: …
More Releases from The Business Research Company
Top Trends Transforming the Fluoropolymer Films Market Landscape in 2025: Techno …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Fluoropolymer Films Industry Market Size Be by 2025?
The fluoropolymer films market has seen strong growth recently. It will expand from $2.5 billion in 2024 to $2.65 billion in 2025 at a CAGR of 5.7%. Growth drivers in the past included high thermal stability, electronics manufacturing…
Driving Digitally Printed Wallpaper Market Growth in 2025: The Role of Rising Ur …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Digitally Printed Wallpaper Market Size Growth Forecast: What to Expect by 2025?
The digitally printed wallpaper market has expanded rapidly in recent years. It will grow from $9.13 billion in 2024 to $10.26 billion in 2025, at a CAGR of 12.4%. Historic growth was fueled by interior design preferences,…
Top Market Shifts Transforming the Biodegradable Paper and Plastic Packaging Mar …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Biodegradable Paper and Plastic Packaging Market Through 2025?
Over the past few years, we've witnessed a significant expansion in the size of the biodegradable paper and plastic packaging market. It is projected to rise from $12.97 billion in 2024 to $14.12 billion…
Acrylic Rubber Market Landscape to 2034: Key Forces Shaping the Next Decade of G …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Acrylic Rubber Market Size By 2025?
The acrylic rubber industry has seen robust growth in the past few years. The market value, which is projected to escalate from $1.63 billion in 2024 to $1.74 billion in 2025, implies a compound annual growth rate (CAGR) of…
More Releases for CIDP
CIDP Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landsca …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Chronic Inflammatory Demyelinating Polyneuropathy pipeline constitutes 2+ key companies continuously working towards developing 4+ Chronic Inflammatory Demyelinating Polyneuropathy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Chronic Inflammatory Demyelinating Polyneuropathy Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Growth, Trends, …
Introduction
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder characterized by progressive weakness and impaired sensory function in the arms and legs due to damage to the myelin sheath surrounding peripheral nerves. Though uncommon, CIDP significantly affects patient quality of life and requires long-term management, often involving immunotherapy, corticosteroids, and plasma exchange.
Over the past decade, improved diagnostic capabilities, greater awareness of rare neurological diseases, and advancements in immunoglobulin therapies…
CIDP Market Emerging Trends and Growth Prospects 2034
Introduction
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) is a rare, immune-mediated neuropathy characterized by progressive or relapsing weakness, sensory loss, and impaired reflexes due to demyelination of peripheral nerves. Unlike acute Guillain-Barré syndrome, CIDP evolves over at least eight weeks and, without timely treatment, can lead to significant long-term disability. The condition encompasses typical CIDP and several clinical variants (e.g., MADSAM/Lewis-Sumner, DADS, pure motor, pure sensory), each with nuanced diagnostic and therapeutic…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
